简介:CHANGESOF6-K-PGF1aRELEASEFROMTHELUMINALSURFACEOFDACRONSEEDEDWITHAUTOLOOUSVENOUSTISSUEFRAGMENTSCHANGESOF6-K-PGF1aRELEASEFROMTH...
简介:Outerbridge-Kashiwagi肱尺关节成形术[1,2](O-K关节成形术)治疗创伤后肘关节僵直,1985年由Kashiwagi设计,通过肘后入路创造性地将鹰嘴窝开窗贯通前后关节腔,清理、松解关节并解除鹰嘴及冠状突的骨赘阻挡,达到清除阻挡、减轻疼痛、增加活动度的目的.我院自1998年应用改良O-K关节成形术治疗创伤后肘关节僵直9例,效果良好.
简介:LFA-1andMac-1,twoβ2integrinmembersconstitutivelyexpressedonneutrophils,mediateleukocyterecruitmentcascadebybindingtothesameligandofICAM-1.TheslowrollingandfirmadhesionofleukocytesrelyonLFA-1whilethecellcrawlingisdependentonMac-1.Wehypothesizedthattheirdistinctroleswerelikelyattributedtothedifferencesinthebindingkineticsorinthediverseresponsesofoutside-inandinside-outsignaling.Inthisstudy,wecomparedtheICAM-1bindingfeaturesbetweensolubleormembrane-expressedLFA-1andMac-1withdifferentaffinityconformationsusingopticaltraptechnique.Ourdataindicatethattheaffinityup-regulationfromwidetype(WT)tohighaffinity(HA)isoff-ratedependentforLFA-1buton-ratedependentforMac-1.Thestructuralbasesofthisnewfindingwerefoundtobeconsistentwithourprevioussimulations.Theseresultsfurtheredourunderstandingontheirfunctiondifferencesundershearflow.
简介:目的新型表面改性技术和改性材料的开发是当今生物医学材料研究的主要方向,羟基磷灰石(HA)是一种最重要的表面改性材料,但较高的脆性和较低的结合强度严重制约了它在临床中的应用.方法本研究首次选用K2Ti6O13作为生物医用Ti合金的表面改性材料,利用KDC法尝试制备了K2Ti6O13涂层,并对涂层的微结构、结合强度和生物活性进行了观察分析与评估.结果利用KDC方法可以成功地原位合成K2Ti6O13涂层,涂层与钛合金基体间结合牢固,结合强度可达24MPa,热膨胀系数的良好匹配是结合强度提高的主要原因.结论涂层粗糙的表面和气孔可为骨的向内生长提供有利位置.经模拟体液浸泡,涂层表面形成了钙磷比接近人体骨骼的钙磷层,表明涂层具有良好的生物活性.
简介:Objective:Toachieveanoptimizedmethodforsolubleexpressionofhumancarboxylesterase1(hCE-1)inescherichiacoilandpurificationbyNi2+-NTAagaroseaffinitychromatography,togetimprovedproteinyieldandpurityforfurtherdevelopmentofhepatocellularcarcinoma(HCC)diagnosisELISAkits.Methods:ThebestantigenepitopesofhCE1werepredictedbycomparingsecondarystructure,flexibleregions,hydrophilicity,antigenicindexsurfaceprobabilityofresidues.Afterwards,pET-42a(+)withaHis-tagandaGST-tagwasappliedtoformrecombinantplasmidpET-42a(+)/hCE1,whichfacilitatedpurificationwhenusingNi2+-NTAagaroseaffinitychromatography.ProteinqualitywasmeasuredbySDS-PAGEandBCAproteinassay.Western-blotidentificationwasalsoperformedtoensurethecorrectexpressionofhCE1protein.Results:Theresiduesfrom500to567nearC-terminalofhCE1proteinwereconsideredthebestepitopeswhichexhibitedhighhydrophilicityandhighsurfaceprobabilityandrelativelyflexiblesecondarystructureandlowhomologycomparedwithhCE2andhCE3.His-hCE1500-567fusionproteinwasachievedbyIPTG-inductedexpressionwithanexpectedmassof42kDa.Afterpurification,thefinalproductwasspeciallyidentified,whichreachedover95%purityandmorethan10mg/Lofmicrobialculture.InWesternblot,thepurifiedfusionproteinwasrecognizedbyanti-hCE1monoclonalantibody,alongwithprevioussequencingvalidation,whichdemonstratedthecorrectpreparationofsolublehCE1protein.Conclusion:ThisisanefficaciousandaffordablestrategytogeneratefusionhCE1ofhighqualityinEcoli,whichfacilitatespreparationofhCE1monoclonalantibodyandfurtherHCCdiagnosisresearch.
简介:目的分析应用Orthofix-微型器治疗第一掌骨基底部Bennett骨折的临床疗效。方法收集2009年1月-2013年1月我院31例采用Orthofix-微型器治疗的第一掌骨基底部Bennett骨折患者。记录患者年龄、性别等基线资料,以及术后上肢臂、肩、手功能调查量表(Disabilitiesofthearm,shoulderandhand,DASH)评分,随访终末期采用指总关节活动度(Totalactionmovement,TAM)评分。结果随访6-24个月,平均14.4月,手术时间为18-40分钟,平均29.1分钟,术中出血量10-30mL,平均14.5mL。术后3月、术后6月及终末期DASH评分之间比较,差异均有统计学意义(P〈0.05)。随访终末期,其中26例解剖复位,5例骨折对线良好,TAM评分优22例,良7例,差2例。随访期间未发生桡神经浅支损伤、钉道感染等并发症。结论Orthofix-微型外固定器治疗Bennett骨折操作简单、疗效满意。
简介:目的通过动物实验观察可吸收材料聚-D,L-乳酸﹙PDLLA﹚腰椎间融合器植入椎体后,在降解过程中的变生物力学变化规律。方法将可吸收腰椎间融合器通过手术植入到犬椎体,经过12、24和36周后分别取材,测定不同时间椎体的轴向抗压强度和抗扭转强度。结果轴向压缩载荷实验显示术后12周,实验组抗压强度明显高于对照组﹙〈0.05﹚;术后24周显示,实验组的抗压强度显著下降﹙〈0.05﹚,对照组的抗压强度有所上升,但不显著﹙〉0.05﹚,实验组的抗压强度明显高于对照组﹙〈0.05﹚;术后36周显示实验组抗压强度无显著性下降﹙〉0.05﹚,实验组的抗压强度与对照组相比无显著性差异﹙〉0.05﹚。抗扭转实验显示,术后12周,实验组的抗扭转强度明显高于对照组﹙〈0.01﹚;术后24周显示,实验组的抗扭转强度显著下降﹙〈0.01﹚,对照组的抗扭转强度有所上升,但不显著﹙〉0.05﹚,实验组的抗扭转强度明显高于对照组﹙〈0.01﹚;术后36周显示实验组抗扭转强度无显著性下降﹙〉0.05﹚,实验组的抗扭转强度与对照组相比无显著性差异﹙〉0.05﹚。结论高分子材料PDLLA的椎间融合器在植骨融合过程中,其力学强度逐渐下降,但在植骨融合部位获得牢固融合前,能维持较高的力学强度,保证了植骨融合的顺利实现,同时由于其最终降解吸收,不会对骨的生长产生应力遮挡,具有一定的积极意义。